ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate strategic update.
- Combined with the cost reductions mentioned above, this will extend the company’s cash runway in 2024.
- 11,737,899) and provided a Notice of Allowance for two additional patents (patent applications 16/993,110 and 17/581,792), providing foundational protection.
- In point of fact, with these 2024 reductions, the company’s core operating expense reductions between 2022 and 2024 are estimated at $22 million, or 70%.
- The company expects that these efforts will come to fruition during the fourth quarter of 2023 and the beginning of 2024.